Charles River Laboratories is navigating a challenging biopharmaceutical environment with stable revenue performance and proactive cost management strategies. However, ongoing pressures in client spending and pricing may hinder growth prospects. While there are opportunities for improvement, particularly in biotech demand and microbial solutions, the company faces significant revenue decline projections for 2025.
Analysis Date: February 19, 2025 Last Updated: May 29, 2025
+106%
+7.5% per year
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
CountryUS
ExchangeNYSE
IndustryMedical - Diagnostics & Research
SectorHealthcare
Market Cap$9.69B
CEOMr. James C. Foster J.D.
Charles River Laboratories International, Inc. (CRL) helps companies develop new medicines and treatments. They provide important services like testing and safety checks for drugs before they reach patients. They also breed special lab animals, like mice and rats, which scientists use to study diseases and test new drugs. In simple terms, CRL supports the healthcare industry by making sure that new health products are safe and effective.
Streams of revenue
Discovery and Safety Assessment:76%
Manufacturing Support:24%
Geographic Distribution
UNITED STATES:56%
Europe:27%
CANADA:13%
Asia Pacific:5%
Core Products
🐁
Research ModelsLab animal models
🧪
Biologics TestingBiologics analysis
🔍
Discovery ServicesDrug discovery
🦠
Microbial SolutionsMicrobial detection
🔬
Preclinical ServicesDrug safety testing
Business Type
Business to Business
Competitive Advantages
Unlock Competitive Advantages Analysis
Discover all competitive advantages and strategic moats that protect CRL's market position.
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Graham Value Metrics
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
📊
Unlock Graham value analysis
Access Benjamin Graham's value investing criteria, intrinsic value calculations, and margin of safety analysis
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Income Statement Flow
Scroll horizontally to see more
About Profitability Metrics
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
📊
Unlock Profitability Metrics
Access detailed profitability metrics with visual gauges and benchmarks
CRL Stock Analysis: Charles River Laboratories International, Inc. Investment Guide
CRL (Charles River Laboratories International, Inc.) is a Healthcare company listed on New York Stock Exchange. The stock has generated 7.5% annual returns with an overall investment score of None/100.
Charles River Laboratories is navigating a challenging biopharmaceutical environment with stable revenue performance and proactive cost management strategies. However, ongoing pressures in client spending and pricing may hinder growth prospects. While there are opportunities for improvement, particularly in biotech demand and microbial solutions, the company faces significant revenue decline projections for 2025.
CRL Key Financial Metrics
CRL financial analysis includes comprehensive valuation ratios, profitability metrics, and financial health indicators. The company has a valuation score of 7.415909036807209/100 with financial health rated 5.8500000000000005/100.
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (CRL) helps companies develop new medicines and treatments. They provide important services like testing and safety checks for drugs before they reach patients. They also breed special lab animals, like mice and rats, which scientists use to study diseases and test new drugs. In simple terms, CRL supports the healthcare industry by making sure that new health products are safe and effective.
CRL Investment Recommendation
Based on our comprehensive analysis of CRL, investors should consider the company's positive performance track record, earnings consistency (10/10 quarters beat expectations), and current valuation metrics when making investment decisions.
Healthcare Sector Analysis
CRL operates in the Medical - Diagnostics & Research industry within the Healthcare sector. This analysis compares Charles River Laboratories International, Inc. performance against industry and sector benchmarks to provide context for investment decisions.
Frequently Asked Questions about CRL Stock
Is CRL a good investment?
CRL (Charles River Laboratories International, Inc.) has generated 7.5% annual returns with an overall score of None/100. Charles River Laboratories is navigating a challenging biopharmaceutical environment with stable revenue performance and proactive cost management strategies. However, ongoing pressures in client spending and pricing may hinder growth prospects. … Investors should consider their risk tolerance and investment goals when evaluating CRL.
What is CRL P/E ratio and valuation?
CRL valuation metrics including P/E ratio, price-to-book ratio, and price-to-sales ratio are analyzed on this page with comparisons to Medical - Diagnostics & Research industry and Healthcare sector benchmarks. The company currently has a valuation score of 7.415909036807209/100.
Should I buy CRL stock now?
The decision to buy CRL stock should be based on comprehensive analysis of financial metrics, market conditions, and individual investment goals. Our analysis provides , financial health score of 5.8500000000000005/100, and detailed performance metrics to help inform your investment decision.
What are CRL financial health indicators?
CRL financial health analysis includes liquidity ratios, debt levels, cash flow metrics, and profitability indicators. The company has a financial health score of 5.8500000000000005/100 based on comprehensive analysis of balance sheet strength and operational efficiency.
How does CRL compare to competitors?
CRL performance is benchmarked against Medical - Diagnostics & Research industry peers and Healthcare sector averages. Our analysis includes comparative valuation ratios, profitability metrics, and growth indicators to provide context for Charles River Laboratories International, Inc.'s market position.
What are CRL historical returns?
CRL has generated 7.5% annual returns over the 10Y. Historical performance analysis includes price appreciation, dividend yields, and total shareholder returns compared to market benchmarks.
CRL Key Investment Metrics Summary
Annual Return: 7.5%
Valuation Score: 7.415909036807209/100
Financial Health Score: 5.8500000000000005/100
Growth Score: -70.5686546119249/100
Earnings Beat Rate: 10/10 quarters
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Exchange: New York Stock Exchange
Market Cap: 9692355348
CRL Investment Thesis
Charles River Laboratories International, Inc. (CRL) represents a moderate investment opportunity in the Healthcare sector. With an overall score of None/100, the company demonstrates areas for financial improvement.
Investment Strengths
Reasonable Price to Sales Ratio
Strong Gross Profit Margin
Operating Profit Margin
Solid Liquidity Ratios
Manageable Debt Levels
Stable Revenue Performance
Successful Cost Management
Strong Free Cash Flow Generation
Diverse Revenue Streams
Anticipated Biotech Demand Growth
Cost Savings Supporting Future Growth
Positive Developments in Microbial Solutions
Investment Risks
Negative Price to Earnings Ratio
Negative Net Profit Margin
Low Return on Equity
Low Cash Ratio
Interest Coverage
Declining DSA Revenue
Pressure on Operating Margins
Client Spending Constraints
Revenue Decline Forecast
Uncertain Recovery Timeline
Competitive Pricing Pressure
We use cookies to analyze site traffic and optimize your site experience.
By accepting, you consent to our use of cookies. Read our Privacy Policy to Learn more.
